Cargando…

Progression after First-Line Cyclin-Dependent Kinase 4/6 Inhibitor Treatment: Analysis of Molecular Mechanisms and Clinical Data

Cyclin-dependent kinase 4/6 inhibitors (CDK4/6iss) are widely used in first-line metastatic breast cancer. For patients with progression under CDK4/6is, there is currently no standard treatment recommended at the category 1 level in international guidelines. The purpose of this article is to review...

Descripción completa

Detalles Bibliográficos
Autores principales: Villa, Federica, Crippa, Alessandra, Pelizzoni, Davide, Ardizzoia, Alessandra, Scartabellati, Giulia, Corbetta, Cristina, Cipriani, Eleonora, Lavitrano, Marialuisa, Ardizzoia, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572355/
https://www.ncbi.nlm.nih.gov/pubmed/37833875
http://dx.doi.org/10.3390/ijms241914427
_version_ 1785120215683563520
author Villa, Federica
Crippa, Alessandra
Pelizzoni, Davide
Ardizzoia, Alessandra
Scartabellati, Giulia
Corbetta, Cristina
Cipriani, Eleonora
Lavitrano, Marialuisa
Ardizzoia, Antonio
author_facet Villa, Federica
Crippa, Alessandra
Pelizzoni, Davide
Ardizzoia, Alessandra
Scartabellati, Giulia
Corbetta, Cristina
Cipriani, Eleonora
Lavitrano, Marialuisa
Ardizzoia, Antonio
author_sort Villa, Federica
collection PubMed
description Cyclin-dependent kinase 4/6 inhibitors (CDK4/6iss) are widely used in first-line metastatic breast cancer. For patients with progression under CDK4/6is, there is currently no standard treatment recommended at the category 1 level in international guidelines. The purpose of this article is to review the cellular mechanisms underlying the resistance to CDK4/6is, as well as treatment strategies and the clinical data about the efficacy of subsequent treatments after CDK4/6is-based therapy. In the first part, this review mainly discusses cell-cycle-specific and cell-cycle-non-specific resistance to CDK4/6is, with a focus on early and late progression. In the second part, this review analyzes potential therapeutic approaches and the available clinical data on them: switching to other CDK4/6is, to another single hormonal therapy, to other target therapies (PI3K, mTOR and AKT) and to chemotherapy.
format Online
Article
Text
id pubmed-10572355
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105723552023-10-14 Progression after First-Line Cyclin-Dependent Kinase 4/6 Inhibitor Treatment: Analysis of Molecular Mechanisms and Clinical Data Villa, Federica Crippa, Alessandra Pelizzoni, Davide Ardizzoia, Alessandra Scartabellati, Giulia Corbetta, Cristina Cipriani, Eleonora Lavitrano, Marialuisa Ardizzoia, Antonio Int J Mol Sci Review Cyclin-dependent kinase 4/6 inhibitors (CDK4/6iss) are widely used in first-line metastatic breast cancer. For patients with progression under CDK4/6is, there is currently no standard treatment recommended at the category 1 level in international guidelines. The purpose of this article is to review the cellular mechanisms underlying the resistance to CDK4/6is, as well as treatment strategies and the clinical data about the efficacy of subsequent treatments after CDK4/6is-based therapy. In the first part, this review mainly discusses cell-cycle-specific and cell-cycle-non-specific resistance to CDK4/6is, with a focus on early and late progression. In the second part, this review analyzes potential therapeutic approaches and the available clinical data on them: switching to other CDK4/6is, to another single hormonal therapy, to other target therapies (PI3K, mTOR and AKT) and to chemotherapy. MDPI 2023-09-22 /pmc/articles/PMC10572355/ /pubmed/37833875 http://dx.doi.org/10.3390/ijms241914427 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Villa, Federica
Crippa, Alessandra
Pelizzoni, Davide
Ardizzoia, Alessandra
Scartabellati, Giulia
Corbetta, Cristina
Cipriani, Eleonora
Lavitrano, Marialuisa
Ardizzoia, Antonio
Progression after First-Line Cyclin-Dependent Kinase 4/6 Inhibitor Treatment: Analysis of Molecular Mechanisms and Clinical Data
title Progression after First-Line Cyclin-Dependent Kinase 4/6 Inhibitor Treatment: Analysis of Molecular Mechanisms and Clinical Data
title_full Progression after First-Line Cyclin-Dependent Kinase 4/6 Inhibitor Treatment: Analysis of Molecular Mechanisms and Clinical Data
title_fullStr Progression after First-Line Cyclin-Dependent Kinase 4/6 Inhibitor Treatment: Analysis of Molecular Mechanisms and Clinical Data
title_full_unstemmed Progression after First-Line Cyclin-Dependent Kinase 4/6 Inhibitor Treatment: Analysis of Molecular Mechanisms and Clinical Data
title_short Progression after First-Line Cyclin-Dependent Kinase 4/6 Inhibitor Treatment: Analysis of Molecular Mechanisms and Clinical Data
title_sort progression after first-line cyclin-dependent kinase 4/6 inhibitor treatment: analysis of molecular mechanisms and clinical data
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572355/
https://www.ncbi.nlm.nih.gov/pubmed/37833875
http://dx.doi.org/10.3390/ijms241914427
work_keys_str_mv AT villafederica progressionafterfirstlinecyclindependentkinase46inhibitortreatmentanalysisofmolecularmechanismsandclinicaldata
AT crippaalessandra progressionafterfirstlinecyclindependentkinase46inhibitortreatmentanalysisofmolecularmechanismsandclinicaldata
AT pelizzonidavide progressionafterfirstlinecyclindependentkinase46inhibitortreatmentanalysisofmolecularmechanismsandclinicaldata
AT ardizzoiaalessandra progressionafterfirstlinecyclindependentkinase46inhibitortreatmentanalysisofmolecularmechanismsandclinicaldata
AT scartabellatigiulia progressionafterfirstlinecyclindependentkinase46inhibitortreatmentanalysisofmolecularmechanismsandclinicaldata
AT corbettacristina progressionafterfirstlinecyclindependentkinase46inhibitortreatmentanalysisofmolecularmechanismsandclinicaldata
AT ciprianieleonora progressionafterfirstlinecyclindependentkinase46inhibitortreatmentanalysisofmolecularmechanismsandclinicaldata
AT lavitranomarialuisa progressionafterfirstlinecyclindependentkinase46inhibitortreatmentanalysisofmolecularmechanismsandclinicaldata
AT ardizzoiaantonio progressionafterfirstlinecyclindependentkinase46inhibitortreatmentanalysisofmolecularmechanismsandclinicaldata